Project Grant 00000F2HL69861A

This Cooperative Agreement award from the Centers for Disease Control and Prevention (CDC) under the Emerging Infections Programs (CFDA 93.317) provides $3,200,000 in funding over a 5-year period starting September 1, 2024 to establish a nationwide cohort of blood donors. The goal is to estimate the burden of respiratory viruses and characterize the immunologic response in this population. The primary awardee, Vitalant, will collaborate with sub-awardees Westat and the American Red Cross to...

This $131,250 Project Grant was awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The grant will support a research project led by Vitalant Research Institute (VRI) to investigate the potential for transfusion-transmitted cerebral amyloid angiopathy (CAA). The key objectives are to: (A) assess the prevalence of amyloid-beta pathology among blood donors using the PTAU217 protein marker, and (B)...

The National Heart, Lung, and Blood Institute (NHLBI) awarded a $513,984 Cooperative Agreement under CFDA 93.837 - Cardiovascular Diseases Research to Emory University on August 15, 2024. The award will support the Southeast Bone Marrow Transplant Consortium (SE-BMTC), a collaboration between Emory, the University of Florida (UF), and the University of Alabama at Birmingham (UAB), to design and activate phase 2 and 3 clinical trials using hematopoietic stem cell and novel adoptive cell-based...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the Cardiovascular Diseases Research federal grant program (CFDA 93.837), aims to evaluate methods for improving the homing and engraftment efficiency of CD34+ cells from sickle cell disease (SCD) patients. The $128,100 award to the New York Blood Center, Inc. will support research to determine if co-infusing the CD34+ cells with their flow-through accessory cells, normally discarded after CD34+ cell...

This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $252,285 to St. Jude Children's Research Hospital Inc. to support a postdoctoral training program in basic and translational research on non-malignant blood disorders. The program aims to address the critical shortage of biomedical trainees focused on classical hematology by attracting and equipping trainees with the knowledge and skills to make new biological...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $1,123,357.00 to support research on the bone marrow microenvironment and its role in regulating blood cell production. The research, to be conducted by the Children's Hospital Medical Center in Cincinnati, Ohio, aims to define the spatial organization and specialized vascular microenvironments within the bone marrow that recruit and...

This Cooperative Agreement award, titled "BMT CORE - PEDIATRIC TRANSPLANTATION AND CELLULAR THERAPY CONSORTIUM (PTCTC): PROVIDING CLINICAL TRIAL ACCESS FOR CHILDREN WITH LIFE THREATENING DISEASES", is funded by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research grant program (CFDA 93.837). The $184,489 award to the National Marrow Donor Program (doing business as Be The Match), a non-profit organization, aims to support a pediatric clinical...

This Project Grant award, provided by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research), will fund a collaborative research program to investigate fundamental questions surrounding anti-ABO(H) antibodies and their target antigens on red blood cells. The $5,187,690 award, with a performance period from August 1, 2024 to July 31, 2029, will support three distinct research projects and complementary core facilities led by a multidisciplinary team of...

This $677,600 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to gain a mechanistic understanding of erythroid progenitor (EP) self-renewal, both in vitro and in vivo. The primary goals are to: Test the hypothesis that the BMI1/RING1B chromatin modulators regulate human self-renewing erythroblast (SRE) self-renewal through epigenetic control of transcription and cholesterol homeostasis. Test the hypothesis that...

This federal Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the CFDA program "Discovery and Applied Research for Technological Innovations to Improve Human Health" (93.286), is providing $487,350 to the Trustees of Tufts College to develop paper-based microsampling devices for stabilizing and metering dried blood and plasma samples. The goal is to enable patient-centric remote blood collection and transport to clinical...